Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party

Article Hematology

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study

Nico Gagelmann et al.

Summary: Hematotoxicity after CAR-T therapy can be managed with hematopoietic stem cell boost (HSCB), which showed a quick response and improved outcomes for sustained moderate to severe neutropenia. 31 patients received HSCB, with an overall neutrophil response rate of 84% and a median response time of 9 days. Patients with shorter duration of neutropenia had significantly better survival outcomes compared to those with longer duration. The 1-year overall survival rate was 59%.

BLOOD ADVANCES (2023)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms

Jennifer N. Brudno et al.

Summary: Prolonged myelosuppression after CAR-T cell therapy is common and poorly understood. Factors such as baseline bone marrow malignancy involvement and the severity of cytokine-release syndrome (CRS) are associated with prolonged or delayed cytopenias.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Article Oncology

Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem

Naman Sharma et al.

Summary: CAR-T immunotherapy, a new treatment modality, modifies the patient's T cells to recognize and kill cancer cells. However, it comes with immune side effects such as cytokine release syndrome and prolonged cytopenia. This review summarizes clinical trials, mechanisms, and interventions on prolonged cytopenia post CAR-T infusion.

CANCERS (2022)

Add to Collection

Letter Hematology

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Kai Rejeski et al.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

Paolo Strati et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 can lead to long-term adverse effects such as cytopenia and immune deficiency. Prolonged monitoring and prophylaxis against opportunistic infections are crucial to improve the long-term safety of this therapy.

HAEMATOLOGICA (2021)

Add to Collection

Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

Add to Collection

Review Oncology